Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
US Judge Dismisses Gautam Adani Criminal Charges 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Airbus Joins Air India A320 Altitude Drop Probe 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
BUFFALO, N.Y., Feb. 16, 2018 -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Johnson Lau, Chief Executive Officer, will present at the 2018 RBC Capital Markets Healthcare Conference in New York City on Wednesday, February 21, 2017 at 11:00 am EST.
The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available at this website until May 22, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
